Starting in 2026, you must submit your invited full proposal in the same cycle as your Letter of Intent. If you are resubmitting an LOI, make sure to include a point-by-point response to previous reviewer comments. Additionally, keep in mind that reviewers now have a strong preference for projects with composition of matter intellectual property (IP) or clear strategies for novel IP development.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: January 12, 2026 (Invited Full Proposal) | September 14, 2026 (Letter of Intent)
Funding Amounts: Up to $5,000,000 per project; multi-year awards; direct costs only.
Summary: Supports IND-enabling studies and early-phase clinical trials for innovative drugs and devices targeting Alzheimer’s disease and related dementias.
Key Information: Only direct costs are allowed; mission-related investment model with milestone-based payments.